<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results</h1>

    <table>
      <tr><th>Ticker</th><td>STIM</td></tr>
      <tr><th>Float</th><td>33.7 M</td></tr>
      <tr><th>IO</th><td>31.39%</td></tr>
      <tr><th>MC</th><td>100.0 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Neuronetics (NASDAQ: STIM) released preliminary unaudited Q4 and full-year 2025 results: Q4 revenue $41.8M (86% YoY as reported; 23% adjusted pro forma), full-year 2025 revenue $149.2M (99% YoY as reported; 15% adjusted pro forma). Q4 NeuroStar revenue was $18.3M (up 9% pro forma) with 49 NeuroStar Advanced Therapy systems shipped. Q4 clinic revenue was $23.5M (up 37% adjusted pro forma); full-year clinic revenue was $87.0M (up 28% adjusted pro forma). The company reported positive operating cash flow of $0.9M in Q4 and ended 2025 with $34.1M in total cash. Results assume the Greenbrook acquisition was effective Jan 1, 2024 and reflect pro forma adjustments and clinic closures. Final audited results will be released before market open on March 17, 2026 with a conference call at 8:30 a.m. ET.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Q4 revenue $41.8M, 86% YoY growth on an as-reported basis and 23% on adjusted pro forma basis</li><li>Full-year 2025 revenue $149.2M, 99% YoY growth on an as-reported basis and 15% on adjusted pro forma basis</li><li>Positive operating cash flow of $0.9M in Q4 2025</li><li>Ended 2025 with $34.1M in total cash (cash, cash equivalents and restricted cash)</li><li>Q4 clinic revenue growth strong: $23.5M, up 37% adjusted pro forma</li><li>Shipped 49 NeuroStar Advanced Therapy systems in Q4</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Results are preliminary and unaudited and subject to change</li><li>Full-year NeuroStar revenue grew only 0.9% on a pro forma basis</li><li>Reported figures depend on assumptions related to the Greenbrook acquisition and clinic closures (pro forma and adjusted pro forma adjustments)</li><li>Press release contains multiple forward-looking statements and lists material risks (including history of losses and dependence on NeuroStar sales)</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/5089e2e9-5c53-4ad5-bd72-56b978f65560" target="_blank">Original Article</a>
    </div>

    <div class="small">STIM â€¢ TradersLink AI News</div>
  </div>
</body>
</html>